Yangyang Zhan

800 Xiangyin Road
Yangpu, 200433, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies.

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: December 09, 2025

PLSCR1 drives chemoresistance in TNBC via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation.

PLSCR1 drives chemoresistance in TNBC via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation.

Journal: Cell death & disease

Published: November 19, 2025

Immunotherapy in Gastrointestinal Cancers: Current Insights.

Immunotherapy in Gastrointestinal Cancers: Current Insights.

Journal: Clinical pharmacology : advances and applications

Published: March 31, 2025

EBNA1BP2 (EBP2) promotes the progression of hepatocellular carcinoma through upregulating the expression of MCM8 and HMGB1.

EBNA1BP2 (EBP2) promotes the progression of hepatocellular carcinoma through upregulating the expression of MCM8 and HMGB1.

Journal: Cell death & disease

Published: February 12, 2025

The Eucommia ulmoides - Achyranthes bidentata pair and their active monomers exert synergistic therapeutic potential for osteoarthritis through the PI3K-AKT pathway.

The Eucommia ulmoides - Achyranthes bidentata pair and their active monomers exert synergistic therapeutic potential for osteoarthritis through the PI3K-AKT pathway.

Journal: Frontiers in pharmacology

Published: February 06, 2025

CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung cancer through the miR-145/HK2 pathway.

CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung cancer through the miR-145/HK2 pathway.

Journal: Cancer letters

Published: November 19, 2024

Drug resistance in TKI therapy for hepatocellular carcinoma: Mechanisms and strategies.

Drug resistance in TKI therapy for hepatocellular carcinoma: Mechanisms and strategies.

Journal: Cancer letters

Published: November 17, 2024

N6-Methyladenosine Modification of circIST1 Promotes Hypoxia-Inducible Factor α-mediated Glycolysis and Progression in Hepatocellular Carcinoma.

N6-Methyladenosine Modification of circIST1 Promotes Hypoxia-Inducible Factor α-mediated Glycolysis and Progression in Hepatocellular Carcinoma.

Journal: MedComm

Published: January 24, 2024

A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter.

A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter.

Journal: MedComm

Published: December 15, 2023

CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.

CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: March 22, 2023

Exosomes as drug delivery system in gastrointestinal cancer.

Exosomes as drug delivery system in gastrointestinal cancer.

Journal: Frontiers in oncology

Published: November 18, 2022

N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells.

N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: August 08, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026